Phase 3 Stomach Cancer Trial, Recruiting NCT01917552 Sponsor: Asan Medical Center Condition: Stomach Cancer
Back to Stomach Cancer

Phase 3 Stomach Cancer Trial, Recruiting

NCT01917552
Recruiting Phase 3

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • People who have had surgery to fully remove stomach cancer or cancer at the junction between the stomach and the food pipe, with the aim of curing the disease
  • People whose cancer is classified as stage IB (using a specific medical staging system) and who also have at least one additional factor that raises the risk of the cancer coming back — these factors include being over 65 years old, being male, or having certain features found in the cancer tissue when examined under a microscope (confirm with trial site)
  • People aged between 18 and 74 years old
  • People who are well enough to carry out daily activities, with only mild limitations at most (based on a standard health scale used in clinical trials)
  • People whose blood counts, kidney function, and liver function are within acceptable ranges as measured by blood tests

Who may not be able to join:

  • Women who are pregnant or breastfeeding
  • Women who could become pregnant and have a positive pregnancy test at the start of the trial, or who have not gone without a menstrual period for at least 12 months (if postmenopausal)
  • People who are sexually active and able to have children but are unwilling to use contraception during the trial and for 3 months after finishing the study treatment
  • People who show any signs that the cancer has spread to other parts of the body
  • People who have already had chemotherapy or radiation treatment for this stomach cancer
  • People who have not yet recovered from serious complications following their stomach surgery
  • People who have had another cancer in the last five years, with the exception of certain fully treated skin cancers or a specific type of fully treated cervical condition
  • People with uncontrolled seizures, significant nervous system disorders, or serious mental health conditions that the trial doctors believe would affect the person's ability to give informed consent or follow the treatment plan
  • People with significant heart problems, such as unstable chest pain, moderate to severe heart failure, serious irregular heartbeat requiring medication, or a heart attack within the last 6 months
  • People who have difficulty absorbing food or medication through their digestive system, or who are unable to swallow tablets
  • People with serious ongoing infections or other serious uncontrolled health conditions
  • People who have received a transplanted organ and are taking medication to prevent rejection
  • People who have taken part in another clinical trial or received an experimental treatment within 4 weeks before joining this trial
  • People who need to take a specific antiviral medicine called sorivudine or closely related drugs such as brivudine
  • People who test positive for HIV

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 26 July 2026
Phase 3: approximately ~65% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.
Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.

Contact this trial

Principal Investigator: Min-Hee Ryu, MD, PhD, Asan Medical Center

Phone: +82230105935

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Phase 3
Registry
ClinicalTrials.gov
Start date
19 August 2013
Est. completion
1 August 2026

Where this trial is recruiting

🇰🇷 South Korea

Primary endpoints

recurrence-free survival

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 26 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov